The University of Chicago has had a major commitment to both laboratory and clinical cancer research since 1930. As part of the clinical translation of that research, University of Chicago, Section of Hematology/Oncology joined the Cancer and Leukemia Group B (CALGB) in 1985. In 1987, we were awarded a five year grant to participate in CALGB activities. After averaging 50-60 patient accruals for the first several years, we accrued 142 patients in 1989, 197 in 1990 and 219 in 1991. This was accomplished by disciplined activity at the University hospital and also by establishing strong affiliated institutions in northern Illinois and Indiana. There are five main goals of this grant: 1) to achieve a patient accrual total of 300-350 patients/year by 1998; 2) to lead and assist CALGB scientific activities in the disease-related committees of respiratory (Drs. Vogelzang and Vokes) breast (Drs. Ratain and Morrow) leukemia (Dr. Larson) and lymphoma (Dr. Schilsky); 3) to lead and assist CALGB scientific activities in the modality committees of correlative science (Drs. Westbrook, Anastasi , and LeBeau), transplantation (Drs. Williams and Bitran) and pharmacology and experimental therapeutics (Drs. Schilsky and Ratain); 4) to provide clinical protocol chairmen for various future protocols; and 5) to actively assist and participate in the CALGB committees of audit, minority initiative, data management, oncology nursing, cancer control, pathology, radiotherapy and surgery. We propose to accomplish these goals by the following methods: 1) to increase accrual from the main member by increasing the numbers of leukemia, myelodysplastia, adjuvant breast and adjuvant colon cancer patients and by generating new ideas for phase I, II, and III protocols, 2) to increase accrual from affiliates by maintaining current accrual rates from our 3 major affiliates and by adding new accrual from Weiss Hospital, Lutheran General Hospital, St. Vincents Hospital and LaGrange Memorial Hospital, 3) to maintain the strong leadership roles of Drs. Ratain, Vokes, Morrow, Larson, Vogelzang, Schilsky, Westbrook, LeBeau, Anastasi, and Williams, within the CALGB, 4) to attract young investigators to the CALGB especially those with a specific laboratory expertise which can be correlated with clinical treatment or outcome, 5) to provide volunteers for the numerous CALGB administrative committees, and 6) to remain firmly committed to serving all members of our respective communities, especially serving the need of women and minorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA041287-08
Application #
3558375
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1986-09-30
Project End
1998-03-31
Budget Start
1993-06-28
Budget End
1994-03-31
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050

Showing the most recent 10 out of 224 publications